Inspire Medical Systems, Inc. (INSP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 350M 700M 1.1B Q4 '17: 28.6M Q1 '18: 33.3M Q2 '18: 38.2M Q3 '18: 44M Q4 '18: 50.6M Q1 '19: 56.8M Q2 '19: 63.9M Q3 '19: 71.7M Q4 '19: 82M Q1 '20: 87.1M Q2 '20: 81.3M Q3 '20: 96.3M Q4 '20: 115.4M Q1 '21: 134.4M Q2 '21: 175.2M Q3 '21: 201M Q4 '21: 233.4M Q1 '22: 262.4M Q2 '22: 300.9M Q3 '22: 348.4M Q4 '22: 407.9M Q1 '23: 466.4M Q2 '23: 526.1M Q3 '23: 570.2M Q4 '23: 624.8M Q1 '24: 660.9M Q2 '24: 705.7M Q3 '24: 755.6M Q4 '24: 802.8M Q1 '25: 840.1M Q2 '25: 861.3M Q3 '25: 882.6M Q4 '25: 912M Q1 '26: 915.2M Q2 '26: 898.7M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 300M 600M 900M Q4 '17: 22.5M Q1 '18: 26.2M Q2 '18: 30.4M Q3 '18: 35.2M Q4 '18: 40.5M Q1 '19: 46.2M Q2 '19: 52.3M Q3 '19: 59.1M Q4 '19: 68.4M Q1 '20: 73.1M Q2 '20: 68.4M Q3 '20: 81.6M Q4 '20: 97.8M Q1 '21: 114.1M Q2 '21: 149.3M Q3 '21: 171.7M Q4 '21: 200.1M Q1 '22: 225.1M Q2 '22: 256.9M Q3 '22: 293.2M Q4 '22: 341.7M Q1 '23: 390.4M Q2 '23: 440M Q3 '23: 479.5M Q4 '23: 528.2M Q1 '24: 559.5M Q2 '24: 598.7M Q3 '24: 640.5M Q4 '24: 679.8M Q1 '25: 711.2M Q2 '25: 727.5M Q3 '25: 749.5M Q4 '25: 778.8M Q1 '26: 785.1M Q2 '26: 774.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q4 '17: -16M Q1 '18: -17.1M Q2 '18: -18.3M Q3 '18: -19.3M Q4 '18: -20.4M Q1 '19: -24M Q2 '19: -26.5M Q3 '19: -30.5M Q4 '19: -34.9M Q1 '20: -42.6M Q2 '20: -57.2M Q3 '20: -58.4M Q4 '20: -56.2M Q1 '21: -55.5M Q2 '21: -45.2M Q3 '21: -45.1M Q4 '21: -39.9M Q1 '22: -40.2M Q2 '22: -41.7M Q3 '22: -49.1M Q4 '22: -47.6M Q1 '23: -51M Q2 '23: -53.6M Q3 '23: -49.9M Q4 '23: -40.3M Q1 '24: -36M Q2 '24: -14.3M Q3 '24: 13.5M Q4 '24: 36.1M Q1 '25: 49.8M Q2 '25: 41.4M Q3 '25: 36.7M Q4 '25: 51M Q1 '26: 51.3M Q2 '26: 54.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-100M -50M 0 50M 100M 150M Q4 '17: -17.5M Q1 '18: -19.5M Q2 '18: -20.6M Q3 '18: -21.3M Q4 '18: -21.8M Q1 '19: -23.6M Q2 '19: -25.4M Q3 '19: -28.9M Q4 '19: -33.2M Q1 '20: -41.2M Q2 '20: -56.7M Q3 '20: -58.8M Q4 '20: -57.2M Q1 '21: -57.2M Q2 '21: -47.2M Q3 '21: -47.1M Q4 '21: -42M Q1 '22: -42.5M Q2 '22: -43.9M Q3 '22: -50.4M Q4 '22: -44.9M Q1 '23: -43.6M Q2 '23: -41.1M Q3 '23: -32.8M Q4 '23: -21.2M Q1 '24: -15.7M Q2 '24: 6M Q3 '24: 33M Q4 '24: 53.5M Q1 '25: 66.5M Q2 '25: 53.1M Q3 '25: 44.6M Q4 '25: 145.4M Q1 '26: 131.1M Q2 '26: 135M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 50M 100M 150M Q4 '17: 6M Q1 '18: 7.1M Q2 '18: 7.8M Q3 '18: 8.7M Q4 '18: 10.1M Q1 '19: 10.6M Q2 '19: 11.6M Q3 '19: 12.6M Q4 '19: 13.6M Q1 '20: 14.1M Q2 '20: 12.9M Q3 '20: 14.7M Q4 '20: 17.6M Q1 '21: 20.3M Q2 '21: 25.9M Q3 '21: 29.3M Q4 '21: 33.3M Q1 '22: 37.3M Q2 '22: 44M Q3 '22: 55.1M Q4 '22: 66.1M Q1 '23: 76M Q2 '23: 86.1M Q3 '23: 90.7M Q4 '23: 96.6M Q1 '24: 101.4M Q2 '24: 107M Q3 '24: 115.1M Q4 '24: 123M Q1 '25: 128.9M Q2 '25: 133.8M Q3 '25: 133.1M Q4 '25: 133.2M Q1 '26: 130.2M Q2 '26: 124.6M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-60M 0 60M 120M 180M Q4 '17: -15.8M Q1 '18: -16.8M Q2 '18: -19M Q3 '18: -19.4M Q4 '18: -18.7M Q1 '19: -23.2M Q2 '19: -30M Q3 '19: -29.4M Q4 '19: -32.8M Q1 '20: -36.7M Q2 '20: -49M Q3 '20: -55M Q4 '20: -53M Q1 '21: -48.7M Q2 '21: -33.5M Q3 '21: -25M Q4 '21: -20.1M Q1 '22: -22.5M Q2 '22: -18.3M Q3 '22: -7M Q4 '22: 11.6M Q1 '23: 23M Q2 '23: 34M Q3 '23: 26.7M Q4 '23: 24.7M Q1 '24: 34.9M Q2 '24: 29.7M Q3 '24: 78.3M Q4 '24: 130.2M Q1 '25: 114.7M Q2 '25: 117.4M Q3 '25: 133.7M Q4 '25: 117M Q1 '26: 136.5M Q2 '26: 157.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-80M -40M 0 40M 80M 120M Q4 '17: -16.2M Q1 '18: -17.1M Q2 '18: -19.2M Q3 '18: -19.5M Q4 '18: -18.9M Q1 '19: -23.7M Q2 '19: -31.4M Q3 '19: -31.8M Q4 '19: -35.6M Q1 '20: -39.4M Q2 '20: -51.2M Q3 '20: -57.3M Q4 '20: -55.5M Q1 '21: -52.2M Q2 '21: -38.3M Q3 '21: -29.7M Q4 '21: -24.8M Q1 '22: -27M Q2 '22: -22.6M Q3 '22: -13.6M Q4 '22: 2.5M Q1 '23: 11.3M Q2 '23: 18.9M Q3 '23: 8.1M Q4 '23: 1M Q1 '24: 3.3M Q2 '24: -9.4M Q3 '24: 38.2M Q4 '24: 91.1M Q1 '25: 78.8M Q2 '25: 85M Q3 '25: 98.8M Q4 '25: 78.5M Q1 '26: 96.7M Q2 '26: 117.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '20: 26.3M Q3 '20: 26.8M Q1 '21: 27.1M Q2 '21: 27.2M Q3 '21: 27.3M Q1 '22: 27.5M Q2 '22: 27.6M Q3 '22: 28.2M Q1 '23: 29.1M Q2 '23: 29.2M Q3 '23: 29.4M Q1 '24: 29.6M Q2 '24: 30.4M Q3 '24: 30.6M Q1 '25: 30.3M Q2 '25: 29.5M Q3 '25: 29.6M Q1 '26: 28.7M Q2 '26: 28.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '17: -14.92 Q1 '18: -16.07 Q2 '18: -12.36 Q3 '18: -9.16 Q4 '18: -5.92 Q1 '19: -1.22 Q2 '19: -1.11 Q3 '19: -1.23 Q4 '19: -1.39 Q1 '20: -1.71 Q2 '20: -2.27 Q3 '20: -2.32 Q4 '20: -2.20 Q1 '21: -2.13 Q2 '21: -1.73 Q3 '21: -1.72 Q4 '21: -1.54 Q1 '22: -1.55 Q2 '22: -1.60 Q3 '22: -1.82 Q4 '22: -1.60 Q1 '23: -1.52 Q2 '23: -1.40 Q3 '23: -1.09 Q4 '23: -0.72 Q1 '24: -0.53 Q2 '24: 0.20 Q3 '24: 1.09 Q4 '24: 1.73 Q1 '25: 2.17 Q2 '25: 1.73 Q3 '25: 1.47 Q4 '25: 4.90 Q1 '26: 4.41 Q2 '26: 4.54 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.